CellSource Co's Total Assets for the quarter that ended in Apr. 2026 was 円6,984 Mil.
Warning Sign:
If a company builds assets at 34.3% a year, faster than its revenue growth rate of 13.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, CellSource Co's average Total Assets Growth Rate was -13.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 16.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 34.30% per year.
During the past 9 years, CellSource Co's highest 3-Year average Total Assets Growth Rate was 52.20%. The lowest was 16.10%. And the median was 42.45%.
Note:
The Net Income data used here is two times the semi-annual (Apr. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
CellSource Co's Asset Turnover for the quarter that ended in Apr. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
CellSource Co Total Assets Related Terms
CellSource Co Total Assets Historical Data
* Premium members only.
The historical data trend for CellSource Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
CellSource Co's Total Assets for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a Total Assets of 円6,984 Mil as of Apr. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on CellSource Co and its competitors.
Is CellSource Co's Total Assets too high?
CellSource Co's current Total Assets is 円6,984 Mil. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Total Assets compare to VRTX and REGN?
CellSource Co's Total Assets of 円6,984 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on CellSource Co and its competitors. CellSource Co's current Total Assets is 円6,984 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.31, compared to a current price of 円347.00 — trading 55.6% below its estimated fair value. The current Total Assets is 円6,984 Mil. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Total Assets is 円6,984 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円347.00 is trading 55.6% below its estimated GF Value™ of 円781.31.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
Total Assets: 円6,984 Mil
GF Value™: 円781.31 vs. price of 円347.00 (55.6% below fair value)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
